Clinical analysis of 43 cases with carcinomas in maxillary sinus by sequent combination therapy.
- Author:
Yanxia BAI
1
;
Liying YAN
;
Yangjing CHEN
;
Liping SONG
;
Ruimin ZHAO
Author Information
1. Department of Otorhinolaryngology Head and Neck Surgery, First Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xi'an 710061, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Carcinoma;
therapy;
Chemotherapy, Adjuvant;
Combined Modality Therapy;
Female;
Humans;
Male;
Maxillary Sinus Neoplasms;
therapy;
Middle Aged;
Quality of Life;
Survival Rate;
Temporal Arteries;
Treatment Outcome;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2008;22(23):1073-1076
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical effects and life quality of 43 cases with carcinomas in maxillary sinus by sequent combination therapy.
METHOD:All the patients were subjected sequent and combination therapy, which included inductive chemotherapy through superficial temporal artery, operation and radical radiation therapy, and of these, 18 patients were added consolidation chemotherapy after combination therapy. Three year survival rate, 5- year survival rate and life quality were observed in a 5 years follow up.
RESULT:All patients completed this therapy, the overall 5-year survival rates were 46.5% (20/43) and 3-year were 65.1% (28/43). None were undertaken orbital exenteration and 12 patients recovered their ability of work and manual labour.
CONCLUSION:The sequent combination therapy is an effective method to enhance the prospective efficacy of treating the carcinoma of maxillary sinus and can raise the local controlling rate. The induced chemotherapy through the temporal artery superficial has many advantages, such as high density of topical remedy, obvious tumor regression after only a cycle chemotherapy, not delaying the surgery opportunity and so on. The consolidation chemotherapy after this combined therapy can reduce the risks of distant metastasis further.
